← Special Reports
EndocrinologyObesity

GLP-1 and Beyond: The Oral Revolution in Obesity Medicine

How oral semaglutide and new dual agonists are reshaping the largest therapy area in pharma

Published 7 July 2026SR-2026-001
EditorMara Voss
CopywritersEditorial Team
Coming Soon

GLP-1 and Beyond: The Oral Revolution in Obesity Medicine

How oral semaglutide and new dual agonists are reshaping the largest therapy area in pharma

Why We Are Covering This

Oral obesity medicine launched in 2026 and captured a third of new prescriptions within eight weeks. Three competing mechanisms are converging on the same market window, and no consensus framework for sequencing them yet exists.

What to Expect

You will leave knowing how oral and injectable GLP-1s compare on real-world efficacy and adherence, which dual agonists are closest to approval, and how coverage decisions will shape prescribing through 2027.

Be first when this report publishes

The Life Science Feed briefing covers every major trial readout, approval, and pipeline shift, weekly.

Get the briefing first
The Life Science Feed
thelifesciencefeed.com · Special Report
SR-2026-00107/26

Related Articles

Isaacs Emphasizes 'Human Touch' in Diabetes Care Beyond TechnologyDiabetes Mellitus Type 2
ADA 2026

Isaacs Emphasizes 'Human Touch' in Diabetes Care Beyond Technology

Diana Isaacs, PharmD, an ADA award winner, advocates for integrating empathetic, patient-centered approaches with advanced diabetes technology to improve outcomes.

9 min readGet the full story
Medically Tailored Meals Cut HbA1c More Than Subsidies in Type 2 DiabetesDiabetes Mellitus Type 2

Medically Tailored Meals Cut HbA1c More Than Subsidies in Type 2 Diabetes

Medically tailored meals reduced HbA1c by 0.59% more than food subsidies in patients with type 2 diabetes, demonstrating superior glycemic control.

11 min readGet the full story
Foundayo Confers Greater HbA1c Reduction Than Farxiga, Ozempic Pill in T2DDiabetes Mellitus Type 2

Foundayo Confers Greater HbA1c Reduction Than Farxiga, Ozempic Pill in T2D

A new investigational therapy, Foundayo, demonstrated superior HbA1c reduction compared to both dapagliflozin and oral semaglutide in type 2 diabetes.

8 min readGet the full story
Elecoglipron Oral GLP-1 Reduces Glucose, Weight in Phase 2Diabetes Mellitus Type 2

Elecoglipron Oral GLP-1 Reduces Glucose, Weight in Phase 2

Elecoglipron, an investigational oral GLP-1 receptor agonist, demonstrated reductions in HbA1c and body weight in phase 2 trials.

11 min readGet the full story
    0:00 / 0:00